An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma.
brachytherapy
chemoradiotherapy
radiotherapy
uterine cervical neoplasms
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
22
01
2022
accepted:
07
07
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
ppublish
Résumé
There are limited reports on outcomes of three-dimensional image-guided brachytherapy (3D-IGBT) for cervical adenocarcinoma in Asia. In a multi-institutional retrospective study, we assessed the clinical outcomes of three-dimensional image-guided brachytherapy for cervical adenocarcinoma or adenosquamous carcinoma (CA/CAC) in Asian countries. Patients who had undergone definitive radiation therapy/concurrent chemoradiotherapy for untreated cervical cancer between 2000 and 2016 were registered. Those who had undergone 3D-IGBT for histologically proven CA/CAC were included. Data on patients' characteristics and treatment were collected, including tumor reduction rate (defined as a percentage of reduction in tumor size before brachytherapy compared with that at diagnosis) and high-risk clinical target volume D Anonymized data of 498 patients were collected. Of the 498 patients, 36 patients met inclusion criteria. The median follow-up period was 39 months. The 3-year OS, LC, and PFS rates were 68.4%, 68.5%, and 44.4%, respectively. After treatment, five patients had tumor re-growth without complete disappearance of the tumor. Two patients developed grade 3 vaginal toxicity or grade 4 rectal toxicity; none developed other severe late toxicities. A tumor reduction rate of > 26.3% was the only significant factor in multivariate analyses, and was associated with significantly better OS ( LC rate of CA/CAC was insufficient despite 3D-IGBT. Meanwhile, tumor reduction rate was associated with LC, OS, and PFS rates. Therefore, CA/CAC may require a different treatment strategy than that applied in cervical squamous cell carcinoma.
Identifiants
pubmed: 36199951
doi: 10.5114/jcb.2022.119451
pii: 47785
pmc: PMC9528827
doi:
Types de publication
Journal Article
Langues
eng
Pagination
311-320Informations de copyright
Copyright © 2022 Termedia.
Déclaration de conflit d'intérêts
Dr Okonogi reports grants and other (investigational drug supply) from AstraZeneca clinical trial, outside the submitted work. Dr Igaki reports grants and personal fees from HekaBio, grants from CICS, grants from Elekta KK, personal fees from AstraZeneca, personal fees from Itochu, personal fees from HIMEDIC, and personal fees from Varian, outside the submitted work. Dr Itami reports grants from Elekta KK, grants and personal fees from Itochu, personal fees from ViewRay, personal fees from Palette Science, personal fees from Alpha-TAU, and personal fees from HekaBio, outside the submitted work. This study received no financial support from any company; thus, there are no conflicts of interests to declare.
Références
J Radiat Res. 2018 Jan 1;59(1):67-76
pubmed: 29186565
Radiother Oncol. 2006 Jan;78(1):67-77
pubmed: 16403584
Brachytherapy. 2018 Sep - Oct;17(5):775-781
pubmed: 29941345
Lancet Oncol. 2021 Apr;22(4):538-547
pubmed: 33794207
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Radiother Oncol. 2015 Apr;115(1):78-83
pubmed: 25805517
J Radiat Res. 2017 May 1;58(3):341-350
pubmed: 27837120
Radiother Oncol. 2009 Nov;93(2):311-5
pubmed: 19679365
J Radiat Res. 2011;52(1):54-8
pubmed: 21293072
Brachytherapy. 2016 Sep-Oct;15(5):598-606
pubmed: 27475482
J Radiat Res. 2020 Mar 23;61(2):275-284
pubmed: 32052042
Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1052-1062
pubmed: 32007365
J Radiat Res. 2020 Jul 6;61(4):608-615
pubmed: 32367130
Cancer. 2004 Mar 1;100(5):1035-44
pubmed: 14983500
BMC Cancer. 2014 Jun 17;14:447
pubmed: 24938757
J Radiat Res. 2017 Jul 1;58(4):543-551
pubmed: 27986859
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Brachytherapy. 2016 Sep-Oct;15(5):562-9
pubmed: 27474180
J Formos Med Assoc. 2018 Oct;117(10):922-931
pubmed: 30025761
J Radiat Res. 2022 May 18;63(3):412-427
pubmed: 35446962
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9
pubmed: 16172231
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):788-96
pubmed: 26530747
BMC Cancer. 2019 Mar 12;19(1):221
pubmed: 30866877
Radiother Oncol. 2016 Sep;120(3):404-411
pubmed: 27452409
Acta Obstet Gynecol Scand. 2014 Jul;93(7):661-8
pubmed: 24666257
Jpn J Clin Oncol. 2010 Aug;40(8):795-9
pubmed: 20444747
Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10
pubmed: 10219815
Cancers (Basel). 2021 May 31;13(11):
pubmed: 34072676
Gynecol Oncol. 2014 Nov;135(2):208-12
pubmed: 25152438
Am J Cancer Res. 2020 Jun 01;10(6):1808-1820
pubmed: 32642292
Cancer Med. 2021 Jul;10(13):4206-4220
pubmed: 34117731